Cardiovascular therapeutics

Building on the team’s expertise in therapeutic development, the CCVHR will continue to build partnerships with local cardiovascular drug development companies including Infensa Bioscience, Dynomics, AstraZeneca and Resverlogix (in addition to others that cannot be listed) and build collaborative links with international companies seeking research and clinical testing opportunities in Australia (Hudson, Cool, King, Palpant).